Tevogen Bio (NASDAQ:TVGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Tevogen Bio Stock Performance

Shares of TVGN opened at $1.10 on Monday. The company has a 50 day moving average of $1.07 and a two-hundred day moving average of $1.27. Tevogen Bio has a twelve month low of $0.26 and a twelve month high of $3.09.

Insiders Place Their Bets

In other Tevogen Bio news, insider Neal Flomenberg sold 88,519 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90. Following the sale, the insider now owns 4,040,485 shares of the company’s stock, valued at approximately $4,444,533.50. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 406,510 shares of company stock valued at $446,763 in the last ninety days. 73.24% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVGN. JPMorgan Chase & Co. grew its holdings in Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after purchasing an additional 16,695 shares during the period. Geode Capital Management LLC increased its position in shares of Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after acquiring an additional 107,566 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Tevogen Bio during the fourth quarter worth approximately $55,000. China Universal Asset Management Co. Ltd. acquired a new position in Tevogen Bio in the fourth quarter worth about $38,000. Finally, Nuveen LLC acquired a new position in Tevogen Bio in the first quarter worth $97,000.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.